Administration releases detailed report on most-favored-nation drug pricing, projects $529 billion savings

The White House Council of Economic Advisers released its most detailed analysis yet of the administration's most-favored-nation drug pricing policy.

The report defines the MFN pricing approach, which requires pharmaceutical companies that have entered confidential agreements with the administration to price any new drug at the level offered to the lowest‑priced market among a set of reference nations.

Using that definition, the analysis estimates that the pledged pricing would save the United States about $529 billion over the next ten years.

However, many of the underlying deal terms remain undisclosed, and experts note that the projected savings rely on assumptions that have not been independently verified, leaving the actual impact on consumers uncertain.